Detection of Early lung Cancer Among Military Personnel (DECAMP)
Abstract
The purpose of this work is to develop and validate molecular biomarkers found in blood, tissues, or other bodily fluids, which may be used for the early detection of lung cancer among military personnel and veterans. Over the course of the fifth year of this award, we have made significant progress towards enrollment in both clinical trials. We have recruited ~60% of the 500 total subjects in the indeterminate pulmonary nodule study (Protocol 1), and ~40% of the 800 total subjects in the longitudinal screening study (Protocol 2). We have ensured that every effort is made to obtain high quality specimens from airway brushings, nasal brushings, and frozen airway biopsy samples. We held our third annual DECAMP consortium meeting in Chicago, IL, including one day of RA-specific meetings. Designated committees meet regularly including the Steering, Adjudication, and Biomarker Committees as well as Imaging and Biostatistics/Analysis Working Groups. Most notably, significant validation work has begun on the Genomics and Proteomics Biomarkers. Finally, we have continued to identify additional funding sources both to supplement infrastructure support within DECAMP and pursue additional biomarker studies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2016
- Accession Number
- AD1035834
Entities
People
- Avrum E. Spira
Organizations
- Boston University